From USFDA
Zydus Cadila has received the final approval from the USFDA to market Diltiazem Hydrochloride Extended-Release Capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain) and certain heart rhythm disorders. It will produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content